非选择性beta受体阻滞剂治疗肝硬化门脉高压症患者研究进展*

doi:10.3969/j.issn.1672-5069.2022.01.036

摘要/Abstract

摘要： 目的肝硬化是各种慢性肝病进展后的病理学阶段,失代偿期常以肝功能减退和门脉高压症为主要临床表现。非选择性β受体阻滞剂(NSBB)可有效降低门脉压力,是近30年来治疗肝硬化门脉高压症的主要方法之一。然而,NSBB改变血流动力学的作用常对患者的循环功能造成影响,是否应用NSBB及其用法用量需因人而异。本文综述了肝硬化患者合理应用NSBB及其争议问题的讨论。

关键词: 肝硬化, 门脉高压症, 非选择性β受体阻滞剂

Abstract: Objective The liver cirrhosis (LC) is the consequence of various chronic liver diseases, with liver function abnormality and portal hypertension occurring in the decompensatory stage. The non-selective beta-blockers (NSBB) has been one of the main medicine for patients with portal hypertension in almost 3 decades, inasmuch as its capacity in reducing portal pressure, though, at the same time, the hemodynamic effects of NSBB can influence the circulatory function of patients. When and how to prescribe NSBB depends on patients' conditions. We aimed to review the reasonable application and controversy of NSBB treatment in cirrhotic patients.

Key words: Liver cirrhosis, Portal hypertension, Non-selective beta-blockers, Adrenergic beta-antagonists

吴玲, 李锋. 非选择性beta受体阻滞剂治疗肝硬化门脉高压症患者研究进展^*[J]. 实用肝脏病杂志, 2022, 25(1): 144-147.

Wu Ling, Li Feng. Administration of non-selective beta-blockers in treatment of patients with liver cirrhosis and portal hypertension[J]. Journal of Practical Hepatology, 2022, 25(1): 144-147.

参考文献

[1] James SL, Abate D, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet,2018,392(10159):1789-1858.
[2] D'Amico G, Morabito A, D'Amico M, et al. Clinical states of cirrhosis and competing risks. J Hepatol,2018,68(3):563-576.
[3] Gracia-Sancho J, Marrone G, Fernandez-Iglesias A. Hepatic microcirculation and mechanisms of portal hypertension. Nat Rev Gastroenterol Hepatol,2019,16(4):221-234.
[4] Fernandez M. Molecular pathophysiology of portal hypertension. Hepatology.2015,61(4):1406-1415.
[5] Villanueva C, Albillos A, Genesca J, et al. Beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet,2019,393(10181):1597-1608.
[6] Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet,2014,383(9930):1749-1761.
[7] McConnell M, Iwakiri Y. Biology of portal hypertension. Hepatol Int,2018,12(Suppl 1):11-23.
[8] Garcia-Tsao G, Bosch J. Varices and variceal hemorrhage in cirrhosis: A new view of an old problem. Clin Gastroenterol Hepatol,2015,13(12):2109-2117.
[9] Aller MA, Arias N, Blanco-Rivero J, et al. Hepatic encephalopathy: Sometimes more portal than hepatic. J Gastroenterol Hepatol,2019,34(3):490-494.
[10] Angeli P, Garcia-Tsao G, Nadim MK, et al. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. J Hepatol,2019,71(4):811-822.
[11] Simonetto DA, Liu M, Kamath PS. Portal hypertension and related complications: Diagnosis and management. Mayo Clin Proc,2019,94(4):714-726.
[12] Baffy G. Potential mechanisms linking gut microbiota and portal hypertension. Liver Int,2019,39(4):598-609.
[13] Bernardi M, Caraceni P. Novel perspectives in the management of decompensated cirrhosis. Nat Rev Gastroenterol Hepatol,2018,15(12):753-764.
[14] Garcia-Tsao G. Current management of the complications of cirrhosis and portal hypertension: Variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Dig Dis,2016,34(4):382-386.
[15] Mehta G, Gustot T, Mookerjee RP, et al. Inflammation and portal hypertension - the undiscovered country. J Hepatol,2014,61(1):155-163.
[16] Moller S, Bendtsen F. The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis. Liver Int,2018,38(4):570-580.
[17] Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med,2010,362(9):823-832.
[18] de Franchis R, Baveno VIF. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol,2015,63(3):743-752.
[19] Villanueva C, Albillos A, Genesca J, et al. Development of hyperdynamic circulation and response to beta-blockers in compensated cirrhosis with portal hypertension. Hepatology,2016,63(1):197-206.
[20] Reiberger T, Mandorfer M. Beta adrenergic blockade and decompensated cirrhosis. J Hepatol,2017,66(4):849-859.
[21] Vorobioff JD, Groszmann RJ. Prevention of portal hypertension: from variceal development to clinical decompensation. Hepatology,2015,61(1):375-381.
[22] Reiberger T, Ferlitsch A, Payer BA, et al. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol,2013,58(5):911-921.
[23] Giannelli V, Lattanzi B, Thalheimer U, et al. Beta-blockers in liver cirrhosis. Ann Gastroenterol,2014,27(1):20-26.
[24] Njei B, McCarty TR, Garcia-Tsao G. Beta-blockers in patients with cirrhosis and ascites: type of beta-blocker matters. Gut,2016,65(8):1393-1394.
[25] Zacharias AP, Jeyaraj R, Hobolth L, et al. Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices. Cochrane Database Syst Rev,2018,10:1-60.
[26] Tripathi D, Stanley AJ, Hayes PC, et al. U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut,2015,64(11):1680-1704.
[27] Ge PS, Runyon BA. Treatment of patients with cirrhosis. N Engl J Med,2016,375(8):767-777.
[28] Bhutta AQ, Garcia-Tsao G, Reddy KR, et al. Beta-blockers in hospitalised patients with cirrhosis and ascites: mortality and factors determining discontinuation and reinitiation. Aliment Pharmacol Ther,2018,47(1):78-85.
[29] Giannelli V, Roux O, Laouenan C, et al. Impact of cardiac function, refractory ascites and beta blockers on the outcome of patients with cirrhosis listed for liver transplantation. J Hepatol,2020,72(3):463-471.
[30] Kimer N, Feineis M, Moller S, et al. Beta-blockers in cirrhosis and refractory ascites: a retrospective cohort study and review of the literature. Scand J Gastroenterol,2015,50(2):129-137.
[31] Leithead JA, Rajoriya N, Tehami N, et al. Non-selective beta-blockers are associated with improved survival in patients with ascites listed for liver transplantation. Gut,2015,64(7):1111-1119.
[32] Mookerjee RP, Pavesi M, Thomsen KL, et al. Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure. J Hepatol,2016,64(3):574-582.
[33] Mandorfer M, Bota S, Schwabl P, et al. Nonselective beta blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology,2014,146(7):1680-1690.
[34] Gao YH, Wang JY, Liu PY, et al. Iron metabolism disorders in patients with hepatitis B-related liver diseases. World J Clin Cases, 2018,6(13):600-610.
[35] Lee NCW, Carella MA, Papa S, et al. High expression of glycolytic genes in cirrhosis correlates with the risk of developing liver cancer. Front Cell Dev Biol, 2018,6:138.
[36] Gimenez P, Garcia-Martinez I, Frances R, et al. Treatment with non-selective beta-blockers affects the systemic inflammatory response to bacterial DNA in patients with cirrhosis. Liver Int,2018,38(12):2219-2227.
[37] Madsen BS, Nielsen KF, Fialla AD, et al. Keep the sick from harm in spontaneous bacterial peritonitis: Dose of beta blockers matters. J Hepatol,2016,64(6):1455-1456.
[38] Kim HY, Cho EJ, Chun S, et al. Red blood cell alloimmunization in Korean patients with myelodysplastic syndrome and liver cirrhosis. Ann Lab Med, 2019,39(2):218-222.
[39] Fortea JI, Puente Á, Ruiz P, et al. Impact of an acute hemodynamic response-guided protocol for primary prophylaxis of variceal bleeding. World J Clin Cases, 2018,6(13):611-623.
[40] Khatri A, Kanaparthy NS, Selvaraj BJ, et al. Primary Klebsiella pneumoniae osteomyelitis with bacteremia and sepsis in a patient with cirrhosis. Case Rep Infect Dis, 2018,2018:3183805.
[41] De Gottardi A, Rautou PE, Schouten J, et al. Porto-sinusoidal vascular disease: proposal and description of a novel entity. Lancet Gastroenterol Hepatol, 2019,4(5):399-411.
[42] Nagai H, Mukozu T, Kobayashi K, et al. Influence of sorafenib on host immunity in patients with liver cirrhosis with advanced hepatocellular carcinoma stratified by etiology.Anticancer Res, 2019,39(4):2183-2191.
[43] Krag A, Wiest R, Albillos A, et al. The window hypothesis: haemodynamic and non-haemodynamic effects of beta-blockers improve survival of patients with cirrhosis during a window in the disease. Gut,2012,61(7):967-969.
[44] Ferrarese A, Tsochatzis E, Burroughs AK, et al. Beta-blockers in cirrhosis: therapeutic window or an aspirin for all? J Hepatol,2014,61(2):449-450.
[45] Garcia-Tsao G. Beta blockers in cirrhosis: The window re-opens. J Hepatol,2016,64(3):532-534.

非选择性beta受体阻滞剂治疗肝硬化门脉高压症患者研究进展^*

Administration of non-selective beta-blockers in treatment of patients with liver cirrhosis and portal hypertension

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	郑小勤, 徐辉, 李丽, 靳华, 汪晓军, 勾春燕. 家族聚集性原发性胆汁性肝硬化患者临床特征分析[J]. 实用肝脏病杂志, 2022, 25(2): 207-210.
[2]	曾议, 李国, 李红翠, 彭雅松, 田峰, 王小军. 熊去氧胆酸治疗原发性胆汁性胆管炎患者疗效及对血清Nrf2和HO-1水平的影响[J]. 实用肝脏病杂志, 2022, 25(2): 211-214.
[3]	郝玉婷, 林洁, 秦杰. 长期接受恩替卡韦治疗的乙型肝炎肝硬化患者血清水通道蛋白8和水通道蛋白9变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2022, 25(2): 243-246.
[4]	王本贤, 李伟, 李东生, 李华. 腹水浓缩回输联合抗感染治疗失代偿期乙型肝炎肝硬化患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(2): 247-250.
[5]	余涛, 付路路, 陈方, 田园. 超声造影灌注时相分析在肝硬化背景下对肝脏增生结节的诊断价值[J]. 实用肝脏病杂志, 2022, 25(2): 267-270.
[6]	何福亮, 马琳, 李悦榕, 王宇, 王民, 冯丽娟, 张冠华, 欧晓娟, 刘福全, 贾继东. 非肝硬化性门脉高压的临床诊断[J]. 实用肝脏病杂志, 2022, 25(1): 1-4.
[7]	张裕, 刘福全. 经颈静脉门体静脉分流术精准技术与合理分流道的建立^*[J]. 实用肝脏病杂志, 2022, 25(1): 5-8.
[8]	陈靖, 朱月永. 无创诊断肝硬化门静脉高压症:血清标志物还是影像学检查？[J]. 实用肝脏病杂志, 2022, 25(1): 9-12.
[9]	徐艳, 于秉楠, 武剑. 自身免疫性肝炎和原发性胆汁性肝硬化患者自身免疫性甲状腺疾病流行率调查^*[J]. 实用肝脏病杂志, 2022, 25(1): 42-45.
[10]	周晓永, 白阳秋, 杨惠, 张炳勇, 曲波. 原发性胆汁性胆管炎患者血清甲状腺激素水平和抗甲状腺抗体阳性率变化^*[J]. 实用肝脏病杂志, 2022, 25(1): 46-49.
[11]	李艳乐, 刘笑宇, 姚建宁, 王春峰, 张连峰, 张学秀. 乙型肝炎肝硬化并发肝性脑病患者血氨水平与认知障碍关系研究^*[J]. 实用肝脏病杂志, 2022, 25(1): 74-78.
[12]	王菁, 毕宁, 方亮, 田园. 乙型肝炎肝硬化并发自发性细菌性腹膜炎患者CD64指数及血清sTREM-1和IL-6水平变化与肠黏膜屏障功能关系研究[J]. 实用肝脏病杂志, 2022, 25(1): 79-82.
[13]	吴晓枫, 黄怡, 杨如杏, 邓少东, 张静莹, 官成浓, 王颖. 原发性胆汁性肝硬化患者外周血丝氨酸蛋白酶抑制剂A1基因多态性分析^*[J]. 实用肝脏病杂志, 2021, 24(6): 855-858.
[14]	石翠翠, 刘彦君, 章瑞南, 李光明, 范建高. 肝硬化患者血脂异常分析^*[J]. 实用肝脏病杂志, 2021, 24(6): 859-862.
[15]	柳梅, 时永红, 郇娟, 陈茂丽. 失代偿期肝硬化患者并发医院内感染病原菌类别及其耐药特点分析^*[J]. 实用肝脏病杂志, 2021, 24(6): 863-866.